Literature DB >> 29108877

PIM kinases: From survival factors to regulators of cell motility.

Niina M Santio1, Päivi J Koskinen2.   

Abstract

PIM kinases are oncogenic serine/threonine kinases, the expression and activities of which are tightly regulated in normal tissues, but upregulated in many types of human malignancies, including both hematological and solid cancers. Since high PIM expression levels have been connected to cancer progression and poor patient survival, PIM kinases have become attractive targets for drug development. Many downstream targets have also been identified, through which PIM kinases promote cell survival, proliferation and metabolism. More recently, PIM kinases have been implicated in regulation of cell motility, which also plays an important role in tumor growth and cancer progression. This review summarizes effects of PIM kinases and their substrates especially on cancer cell migration, invasion and metastatic growth, based on data from cell-based assays, animal experiments and patients.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Invasion; Metastasis; Migration; Motility; PIM kinases

Mesh:

Substances:

Year:  2017        PMID: 29108877     DOI: 10.1016/j.biocel.2017.10.016

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  15 in total

Review 1.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31

2.  Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.

Authors:  Shilpak Chatterjee; Paramita Chakraborty; Anusara Daenthanasanmak; Supinya Iamsawat; Gabriela Andrejeva; Libia A Luevano; Melissa Wolf; Uday Baliga; Carsten Krieg; Craig C Beeson; Meenal Mehrotra; Elizabeth G Hill; Jeffery C Rathmell; Xue-Zhong Yu; Andrew S Kraft; Shikhar Mehrotra
Journal:  Clin Cancer Res       Date:  2018-10-16       Impact factor: 12.531

Review 3.  A systematic review on active sites and functions of PIM-1 protein.

Authors:  Youyi Zhao; Aziz Ur Rehman Aziz; Hangyu Zhang; Zhengyao Zhang; Na Li; Bo Liu
Journal:  Hum Cell       Date:  2022-01-09       Impact factor: 4.174

Review 4.  Micro RNAs Promoting Growth and Metastasis in Preclinical In Vivo Models of Subcutaneous Melanoma.

Authors:  Ulrich H Weidle; Simon AuslÄnder; Ulrich Brinkmann
Journal:  Cancer Genomics Proteomics       Date:  2020 Nov-Dec       Impact factor: 4.069

5.  PIM kinases inhibit AMPK activation and promote tumorigenicity by phosphorylating LKB1.

Authors:  Kwan Long Mung; William B Eccleshall; Niina M Santio; Adolfo Rivero-Müller; Päivi J Koskinen
Journal:  Cell Commun Signal       Date:  2021-06-30       Impact factor: 5.712

6.  Leflunomide Synergizes with Gemcitabine in Growth Inhibition of PC Cells and Impairs c-Myc Signaling through PIM Kinase Targeting.

Authors:  Ralf Buettner; Corey Morales; Xiwei Wu; James F Sanchez; Hongzhi Li; Laleh G Melstrom; Steven T Rosen
Journal:  Mol Ther Oncolytics       Date:  2019-05-17       Impact factor: 7.200

7.  Phosphorylation of NFATC1 at PIM1 target sites is essential for its ability to promote prostate cancer cell migration and invasion.

Authors:  Sini K Eerola; Niina M Santio; Sanni Rinne; Petri Kouvonen; Garry L Corthals; Mauro Scaravilli; Giovanni Scala; Angela Serra; Dario Greco; Pekka Ruusuvuori; Leena Latonen; Eeva-Marja Rainio; Tapio Visakorpi; Päivi J Koskinen
Journal:  Cell Commun Signal       Date:  2019-11-15       Impact factor: 5.712

8.  PIM-induced phosphorylation of Notch3 promotes breast cancer tumorigenicity in a CSL-independent fashion.

Authors:  Sebastian K J Landor; Niina M Santio; William B Eccleshall; Valeriy M Paramonov; Ellen K Gagliani; Daniel Hall; Shao-Bo Jin; Käthe M Dahlström; Tiina A Salminen; Adolfo Rivero-Müller; Urban Lendahl; Rhett A Kovall; Päivi J Koskinen; Cecilia Sahlgren
Journal:  J Biol Chem       Date:  2021-03-26       Impact factor: 5.157

Review 9.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31

10.  PIM1 accelerates prostate cancer cell motility by phosphorylating actin capping proteins.

Authors:  Niina M Santio; Veera Vainio; Tuuli Hoikkala; Kwan Long Mung; Mirka Lång; Riitta Vahakoski; Justyna Zdrojewska; Eleanor T Coffey; Elena Kremneva; Eeva-Marja Rainio; Päivi J Koskinen
Journal:  Cell Commun Signal       Date:  2020-08-08       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.